阿普雷米司特：对局限于指甲的牛皮癣的实际疗效和安全性

IF 3.1 4区医学 Q2 DERMATOLOGY

Annales De Dermatologie Et De Venereologie Pub Date : 2025-05-03 DOI:10.1016/j.annder.2025.103377

M. Iorizzo , G. Damiani , S.R. Lipner , A. Pacifico , D. Rigopoulos , A. Sechi , A. Villani , I. Zaraa , B. Richert

{"title":"阿普雷米司特：对局限于指甲的牛皮癣的实际疗效和安全性","authors":"M. Iorizzo , G. Damiani , S.R. Lipner , A. Pacifico , D. Rigopoulos , A. Sechi , A. Villani , I. Zaraa , B. Richert","doi":"10.1016/j.annder.2025.103377","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>Apremilast, an oral phosphodiesterase inhibitor, offers advantages in psoriasis patients in whom biologics are not approved or accepted and where topical treatments have failed. Psoriasis involving the nails, scalp, and genitals is difficult to treat and is associated with a significant decrease in quality of life, requiring an effective treatment.</div></div><div><h3>Objectives</h3><div>This study aimed to retrospectively assess the efficacy and safety of apremilast 30 mg twice daily in treating psoriasis limited to the nails.</div></div><div><h3>Methods</h3><div>The charts of 55 adult patients with nail psoriasis treated with apremilast were retrospectively evaluated. Baseline characteristics, including the nail psoriasis severity index (NAPSI) and dermatology life quality index (DLQI), were recorded.</div></div><div><h3>Results</h3><div>At 6 months of treatment, a statistically significant decrease in both the NAPSI score (44.7 ± 26.9 vs. 19.03 ± 14.2) and the DLQI score (14.5 ± 5 vs. 7.2 ± 4.1) was observed (<em>p</em> < 0.01). None of the patients discontinued the treatment due to side effects.</div></div><div><h3>Conclusions</h3><div>This study shows improvements in nail psoriasis severity and quality of life with apremilast treatment. Despite potential confounders like psoriatic arthritis, smoking, and manual work, consistent improvements were observed. Apremilast appears to be a valuable treatment option for nail psoriasis. However, further prospective studies are necessary to address the limitations of this retrospective analysis and explore additional endpoints.</div></div>","PeriodicalId":7900,"journal":{"name":"Annales De Dermatologie Et De Venereologie","volume":"152 2","pages":"Article 103377"},"PeriodicalIF":3.1000,"publicationDate":"2025-05-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Apremilast: Real-life efficacy and safety in psoriasis limited to the nails\",\"authors\":\"M. Iorizzo , G. Damiani , S.R. Lipner , A. Pacifico , D. Rigopoulos , A. Sechi , A. Villani , I. Zaraa , B. Richert\",\"doi\":\"10.1016/j.annder.2025.103377\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>Apremilast, an oral phosphodiesterase inhibitor, offers advantages in psoriasis patients in whom biologics are not approved or accepted and where topical treatments have failed. Psoriasis involving the nails, scalp, and genitals is difficult to treat and is associated with a significant decrease in quality of life, requiring an effective treatment.</div></div><div><h3>Objectives</h3><div>This study aimed to retrospectively assess the efficacy and safety of apremilast 30 mg twice daily in treating psoriasis limited to the nails.</div></div><div><h3>Methods</h3><div>The charts of 55 adult patients with nail psoriasis treated with apremilast were retrospectively evaluated. Baseline characteristics, including the nail psoriasis severity index (NAPSI) and dermatology life quality index (DLQI), were recorded.</div></div><div><h3>Results</h3><div>At 6 months of treatment, a statistically significant decrease in both the NAPSI score (44.7 ± 26.9 vs. 19.03 ± 14.2) and the DLQI score (14.5 ± 5 vs. 7.2 ± 4.1) was observed (<em>p</em> < 0.01). None of the patients discontinued the treatment due to side effects.</div></div><div><h3>Conclusions</h3><div>This study shows improvements in nail psoriasis severity and quality of life with apremilast treatment. Despite potential confounders like psoriatic arthritis, smoking, and manual work, consistent improvements were observed. Apremilast appears to be a valuable treatment option for nail psoriasis. However, further prospective studies are necessary to address the limitations of this retrospective analysis and explore additional endpoints.</div></div>\",\"PeriodicalId\":7900,\"journal\":{\"name\":\"Annales De Dermatologie Et De Venereologie\",\"volume\":\"152 2\",\"pages\":\"Article 103377\"},\"PeriodicalIF\":3.1000,\"publicationDate\":\"2025-05-03\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Annales De Dermatologie Et De Venereologie\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0151963825000365\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"DERMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Annales De Dermatologie Et De Venereologie","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0151963825000365","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"DERMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

apremilast是一种口服磷酸二酯酶抑制剂，在生物制剂未被批准或接受以及局部治疗失败的银屑病患者中具有优势。涉及指甲、头皮和生殖器的牛皮癣很难治疗，并且与生活质量显著下降有关，需要有效的治疗。目的回顾性评价阿普米司特30 mg每日2次治疗局限于指甲的银屑病的疗效和安全性。方法对55例成人甲银屑病阿普米司特治疗的临床资料进行回顾性分析。记录基线特征，包括甲牛皮癣严重程度指数（NAPSI）和皮肤科生活质量指数（DLQI）。 6个月的治疗,于(英格兰中北部)显著降低在NAPSI得分(44.7 ±  26.9和19.03±14.2 )和DLQI得分(14.5 ± 5和7.2 ±4.1 )观察(p & lt; 0.01)。没有一个病人因为副作用而停止治疗。结论本研究显示阿普米司特治疗可改善甲牛皮癣的严重程度和生活质量。尽管存在银屑病关节炎、吸烟和体力劳动等潜在的混杂因素，但观察到持续的改善。阿普拉米司特似乎是治疗指甲牛皮癣的一个有价值的选择。然而，需要进一步的前瞻性研究来解决回顾性分析的局限性并探索其他终点。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Apremilast: Real-life efficacy and safety in psoriasis limited to the nails

Background

Apremilast, an oral phosphodiesterase inhibitor, offers advantages in psoriasis patients in whom biologics are not approved or accepted and where topical treatments have failed. Psoriasis involving the nails, scalp, and genitals is difficult to treat and is associated with a significant decrease in quality of life, requiring an effective treatment.

Objectives

This study aimed to retrospectively assess the efficacy and safety of apremilast 30 mg twice daily in treating psoriasis limited to the nails.

Methods

The charts of 55 adult patients with nail psoriasis treated with apremilast were retrospectively evaluated. Baseline characteristics, including the nail psoriasis severity index (NAPSI) and dermatology life quality index (DLQI), were recorded.

Results

At 6 months of treatment, a statistically significant decrease in both the NAPSI score (44.7 ± 26.9 vs. 19.03 ± 14.2) and the DLQI score (14.5 ± 5 vs. 7.2 ± 4.1) was observed (p < 0.01). None of the patients discontinued the treatment due to side effects.

Conclusions

This study shows improvements in nail psoriasis severity and quality of life with apremilast treatment. Despite potential confounders like psoriatic arthritis, smoking, and manual work, consistent improvements were observed. Apremilast appears to be a valuable treatment option for nail psoriasis. However, further prospective studies are necessary to address the limitations of this retrospective analysis and explore additional endpoints.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Annales De Dermatologie Et De Venereologie 医学-皮肤病学

CiteScore

1.40

自引率

0.00%

发文量

审稿时长

81 days

期刊介绍： Les Annales de dermatologie sont le rendez-vous mensuel incontournable de toute la dermatologie francophone, grâce à leur comité de rédaction qui assure une sélection rigoureuse des articles selon les normes de l''édition scientifique internationale. Une revue didactique, véritable aide à la pratique médicale quotidienne Pour compléter et enrichir la partie scientifique, la rubrique Formation médicale continue propose aux lecteurs des textes didactiques et interactifs (Cas pour diagnostic, Notes de pharmacovigilance, la Question du praticien, Dermatologie chirurgicale, la Sélection bibliographique du mois...) qui les font bénéficier d''une formation post-universitaire diversifiée et de qualité. La revue consacre également un espace pour la publication de questions des lecteurs auxquelles des experts apportent une réponse.